SlideShare une entreprise Scribd logo
1  sur  25
Presentation on
PRESENTATION ON
GLAUCOMA
PRESENTED BY:
AYESHA RUQSAR
CONTENTS:
INTRODUCTION.
ETIOLOGY.
PATHOPHYSIOLOGY.
GLAUCOMA CLASSIFICATION.
CLINICAL MANIFESTATION.
DIAGNOSIS.
TREATMENT.
REFERENCES

•Glaucoma refers to a group of
ophthalmic disorders characterized
by neuropathy of the optic nerve and
progressive loss of retinal ganglion
cells,
VISUAL
FIELD
LOSS
OPTIC
NERVE
DAMAGE
GLAUCO
MA
INCREASE
IOP
•Which leads to
permanent
deterioration of the
visual field eventually
lead to blindness.
ETIOLOGY
• All types of glaucoma – progressive optic neuropathy due to
the death of retinal ganglion cells(RGCs)
• RGCs death is initiated by block in transport of neurotrophins
from brain to RGCs
damaging cascade activation
Apoptosis of RGCs
• RGCs death – loss of retinal fibers – optic neuropathy & visual
field defects
• Mechanical theory :
↑IOP – mechanical stretch of lamina cribtosa –
axonal deformation & altered capillary blood
flow -- ↓neurotrophins to reach RGC`s
(normal IOP pressure is 5-22mm/Hg)
• Pressure independent factors :
- Failure of autoregulation
- Vasospasm
- Systemic hypotension
- Blood / fluid loss
• Excitotoxicity theory:
glutamate , oxygen free radicals, nitric oxide.
Intraocular pressure is a function of
production of liquid aqueous humour by
the ciliary processes of the eye, and its
drainage through the trabecular
meshwork. Aqueous humor flows from
the ciliary processes into the posterior
chamber, bounded posteriorly by
the lens and the zonules of Zinn, and
anteriorly by the iris. It then flows
through the pupil of the iris into
the anterior chamber, bounded posteriorly
by the iris and anteriorly by the cornea.
From here, the trabecular meshwork
drains aqueous humor via the scleral
venous sinus (Schlemm's canal)
into scleral plexuses and general blood
circulation.
MECHANISM OF PRODUCTION OF AQUEOUS
HUMOUR AND ITS OUFLOW
PATHOPHYSIOLOGY
A- POAG :
• Increased IOP causes retinal ganglion cell axons
to undergo mechanical stress, alters axonal
protein transport, and decreases blood supply to
the retina and the optic nerve leading to tissue
ischemia.
• The level of IOP is related to the death of retinal
ganglion cell and optic nerve fibers.
B- PACG :
Involves Two major mechanisms of
Mechanical obstruction of trabecular
meshwork by the peripheral iris include
1- Pupillary block (more common)
2- Iris plateau.
• Both of these mechanisms result in the
occlusion of aqueous humor outflow
causing IOP elevation at extreme levels
that can lead to vision loss in hrs to days.
GLAUCOMA CLASSIFICATION
CLINICAL MANIFESTATION
 A- POAG: General
• POAG is usually bilateral with asymmetric disease
progression
Symptoms:
1. Loss of peripheral vision.
2. Presence of scotomata (blind spots) in vision field.
Signs:
Ophthalmoscopic examination may reveal
1.Optic nerve head (optic disc) cupping.
2.Large cup-to-disc ratio.
3.Notching of the optic nerve head rim.
4.Splinter hemorrhages (using a slit-lamp biomicroscope)
B- PACG: General
(Medical emergency due to high risk of vision loss)
• Unilateral in presentation , the other eye is at risk.
Symptoms
1. Ocular pain.
2. Red eye.
3. Blurry vision.
4. Halos around lights.
• Nausea/vomiting.
• Headache / Diaphoresis.
Signs
1. Cloudy cornea
2. Conjunctival hyperemia.
3. Pupil semidilated and fixed to light
4. Eye will be harder on palpation.a
DIAGNOSIS
Eye pressure test (intraocular
pressure).
Anterior chamber angle exam.
Optic angle exam.
Visual field test.
TREATMENT :
1. NON PHARMACOLOGICAL
TREATMENT.
2. PHARMACOLOGICAL
TREATMENT.
Non
pharmacol
-ogical
treatment
1. Eat
healthy
diet
2. Maintain
good
health
3. Avoid
stress
4. Go for
aromatothe
rapy,
acupunctur
e.
5. Avoid
caffeine,
alcohol,
watching tv
etc.,.
6. Avoid
allergic
foods.
NON PHARMACOLOGICAL
TREATMENTS
PHARMACOLOGICAL TREATMENT
 Ophthalmic Drugs for Glaucoma Lowering IOP by
1-REDUCING PRODUCTION OF AQUEOUS
HUMOR:
β-Blockers. α2Adrenergic Agonists
Carbonic Anhydrase Inhibitors.
2-DECREASING THE RESISTANCE TO OUTFLOW
OF AQUEOUS HUMOR THROUGH TRABECULAR
MESHWORK:
cholinergics and cholinesterase inhibitors.
3-IMPROVING THE OUTFLOW OF AQUEOUS
HUMOR:
prostaglandins (uveoscleral outflow)
sympathomimetics (trabecular meshwork and
the uveoscleral outflow).
A.TOPICAL Β-ADRENERGIC BLOCKING
DRUGS
Includes:
1. Non-selective: Timolol, Levobunolol, Metipranolol &
Carteolol.
2. β1-Selective: Betaxolol.
-Dosing: 1 drop BID
-Side effects:
1- Bronchospasm.
2- Bradycardia.
3- Hypotension.
4- CHF exacerbation.
5- Mask hypoglycemia.
6- Tachyphylaxis (20% to 50% of pts)
. -Nasolacrimal occlusion is a technique to decrease amount of
drug absorbed systemically and decrease the incidence of side
effects and improve medication effectiveness.
Contraindications
1- Asthma
2- COPD
3- Sinus bradycardia
4- 2nd or 3rd degree heart failure 16
Betanolol can be used
B. A2-ADRENERGIC AGONISTS
-Includes: Brimonidine(more selective) & Apraclonidine.
-Brimonidine: (Effective long-term monotherapy / adjunctive
therapy)
- Apraclonidine (Short-term use only due to high rate of
tachyphylaxis)
Used for prevention & ttt of postsurgical IOP elevations.
-Dosing: 1 drop BID to TID.
-Side effects:
1-Blepharoconjunctivitis.
2-Foreign body sensation.
3-Papillary mydrasis (Apraclonidine).
4-Eyelid retraction(Apraclonidine).
5-Mild systemic hypotension and lethargy.
( Brimonidine pass BBB ).
Contraindications
1. hypersensitivity.
2. Patients receiving
MOA inhibior therapy.
C. CARBONIC ANHYDRASE INHIBITORS
1- Topical agents :
-Includes: Dorzolamide and Brinzolamide.
-Dosing: 1 drop BID with beta blockers or TID alone.
-Combination of Timolol+Dorzolamide is commonly
used
-Side effects:
1-Burning.
2-Stinging.
3-Itching.
4-Dry eyes.
5-Conjunctivitis
Contraindications
patients with history of
hypersensitivity to
sulphonamides.
2- Orally-administered CAIs:
-Includes: Acetazolamide , Dichlorphenamide,
and Methazolamide.
-Dosing: 250-1000mg daily , given in divided
doses for amount over 250mg.
-Side effects:
1-Paresthesia of hands and feet.
2-Hypokalemia and hyponatremia.
3-Nephrolethiasis and renal failure.
4-Hepatic insufficiency.
5-Blooddyscrasias from bone marrow
suppression
Contraindications:
1-Hypokalemia.
2-Hyponatremia
D. CHOLINERGICS AND CHOLINESTERASE
INHIBITORS
1- CHOLINERGICS:
-Includes: Pilocarpine and Carbachol.
-Dosing:1–2 drops TID or QID.
-Used with caution for closed angle
-Side effects:(due to miosis)
1-Brow ache and headache.
2-Affect night vision.
3-Bradycardia at high conc.
4-Retinal detachment.
5-Lacrimation, myopia, blurred vision.
Contraindications:
1. Severe myopia to avoid
detachment.
2. pregnancy
2- CHOLINESTERASE INHIBITORS:
Includes: Echothiophate iodide &Demecarium
bromide.
-Irreversible AchE inhibitors e’ long durations of
action.
-Stop at least 1 week before general surgical
procedure.
Dosing: 1 drop BID.
Side effects:
1- Depletion of systemic cholinesterase and
pseudocholinesterase.
2- Cataracts: occur in 30–50% of elderly patients
using these drugs for at least 6 months.
E. PROSTAGLANDINS
Includes: Latanoprost, Bimatoprost, Travoprost.
-First-line alternatives to topical β-blockers.
-Patients required to lower IOP by greater than 25%.
-Lower IOP by 25% to 35% (Lower nocturnal IOP).
Dosing: 1 drop once a day at bedtime
Side effects:
1- Conjunctival hyperemia.
2- Stinging on instillation.3- Inc. in iris pigmentation.
4- Hypertrichosis.
5- Eyelashes darkening.
F. SYMPATHOMIMETICS
Includes: DIPIVEFRIN HCL , EPINEPHRINE.
-IOP is reduced by 20–25%.
-Last line agents due to their systemic S.E. Profile
Dosing:1 drop BID.
Intolerance to ocular adverse effects leads to
discontinuation of epinephrine in 80% of patients.
Side effects:
1-Burning, tearing.
2-Reactive conjunctival hyperemia.
3-Allergic blepharoconjunctivitis.
4-Mydriasis → Blurring of vision.
THANK YOU

Contenu connexe

Tendances

MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA
MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA
MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA Rishabh Sharma
 
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...Bikash Sapkota
 
Ocular NSAIDs and Steroids
Ocular NSAIDs and SteroidsOcular NSAIDs and Steroids
Ocular NSAIDs and SteroidsAayush Chandan
 
pharmacotherapy in glaucoma
pharmacotherapy in glaucomapharmacotherapy in glaucoma
pharmacotherapy in glaucomaSamten Dorji
 
Medical treatment of primary open angle glaucoma
Medical treatment of primary open angle glaucomaMedical treatment of primary open angle glaucoma
Medical treatment of primary open angle glaucomaAdithya Phadnis
 
Primary open angle glaucoma
Primary open angle glaucomaPrimary open angle glaucoma
Primary open angle glaucomaketan bhardwaj
 
Bacterial conjunctivitis Pharmacotherapy
Bacterial conjunctivitis PharmacotherapyBacterial conjunctivitis Pharmacotherapy
Bacterial conjunctivitis PharmacotherapyPranatiChavan
 
Pilocarpine use in glaucoma
Pilocarpine use in glaucomaPilocarpine use in glaucoma
Pilocarpine use in glaucomaNidhi Sharma
 
Components of lubricating agents
Components of lubricating agentsComponents of lubricating agents
Components of lubricating agentsSmriti Ranabhat
 
Pharmacotherapy of glaucoma
Pharmacotherapy of  glaucoma Pharmacotherapy of  glaucoma
Pharmacotherapy of glaucoma DrSnehaDange
 

Tendances (20)

Anti glaucoma drugs
Anti glaucoma drugsAnti glaucoma drugs
Anti glaucoma drugs
 
MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA
MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA
MYDRIATIC AND MIOTIC AGENTS AND DRUGS USED IN GLAUCOMA
 
Glaucoma
Glaucoma Glaucoma
Glaucoma
 
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 
Ocular NSAIDs and Steroids
Ocular NSAIDs and SteroidsOcular NSAIDs and Steroids
Ocular NSAIDs and Steroids
 
pharmacotherapy in glaucoma
pharmacotherapy in glaucomapharmacotherapy in glaucoma
pharmacotherapy in glaucoma
 
Contact lens solutions
Contact lens solutionsContact lens solutions
Contact lens solutions
 
Medical treatment of primary open angle glaucoma
Medical treatment of primary open angle glaucomaMedical treatment of primary open angle glaucoma
Medical treatment of primary open angle glaucoma
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 
ANTI GLAUCOMA DRUGS
ANTI GLAUCOMA DRUGSANTI GLAUCOMA DRUGS
ANTI GLAUCOMA DRUGS
 
Viral conjunctivitis
Viral conjunctivitisViral conjunctivitis
Viral conjunctivitis
 
Primary open angle glaucoma
Primary open angle glaucomaPrimary open angle glaucoma
Primary open angle glaucoma
 
Bacterial conjunctivitis Pharmacotherapy
Bacterial conjunctivitis PharmacotherapyBacterial conjunctivitis Pharmacotherapy
Bacterial conjunctivitis Pharmacotherapy
 
Pilocarpine use in glaucoma
Pilocarpine use in glaucomaPilocarpine use in glaucoma
Pilocarpine use in glaucoma
 
Glaucoma ppt
Glaucoma pptGlaucoma ppt
Glaucoma ppt
 
Tear film test
Tear film testTear film test
Tear film test
 
Components of lubricating agents
Components of lubricating agentsComponents of lubricating agents
Components of lubricating agents
 
Pharmacotherapy of glaucoma
Pharmacotherapy of  glaucoma Pharmacotherapy of  glaucoma
Pharmacotherapy of glaucoma
 
Ocular hypotensive drugs
Ocular hypotensive drugsOcular hypotensive drugs
Ocular hypotensive drugs
 

Similaire à GLAUCOMA PPT

Pharmacotherapy of glaucoma
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucomaRenuka Harwani
 
Ocular pharmacology ii, dr.kurinchi, 22.06.17
Ocular pharmacology ii, dr.kurinchi, 22.06.17Ocular pharmacology ii, dr.kurinchi, 22.06.17
Ocular pharmacology ii, dr.kurinchi, 22.06.17ophthalmgmcri
 
Pharmacotherapy of glaucoma
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucomaDr.Arka Mondal
 
Ocular pharmacology
Ocular pharmacologyOcular pharmacology
Ocular pharmacologyDr Kundan
 
Mellss yr4 opthalmology glaucoma primary open angle
Mellss yr4 opthalmology glaucoma  primary open angleMellss yr4 opthalmology glaucoma  primary open angle
Mellss yr4 opthalmology glaucoma primary open anglenur amalina aminuddin baki
 
Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...
Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...
Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...Zeeshan Hameed
 
Primary open angle glaucoma (poag)
Primary open angle glaucoma (poag)Primary open angle glaucoma (poag)
Primary open angle glaucoma (poag)Om Patel
 
Primary open angle glaucoma(POAG)
Primary open angle glaucoma(POAG)Primary open angle glaucoma(POAG)
Primary open angle glaucoma(POAG)rakshyabasnet1
 
recent advances in pharmacotherapy of Glaucoma
recent advances in pharmacotherapy of Glaucoma recent advances in pharmacotherapy of Glaucoma
recent advances in pharmacotherapy of Glaucoma DrShrey Bhatia
 
Pharmacotherapy & recent advances in glaucoma management
Pharmacotherapy & recent advances in glaucoma managementPharmacotherapy & recent advances in glaucoma management
Pharmacotherapy & recent advances in glaucoma managementJeffrey Pradeep Raj
 
Primary open angle glaucoma
Primary open angle glaucomaPrimary open angle glaucoma
Primary open angle glaucomaAmr Mounir
 
primaary open angle glaucoma presentation
primaary open angle glaucoma presentationprimaary open angle glaucoma presentation
primaary open angle glaucoma presentationSandeepKrishnan42
 
Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke
Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke  Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke
Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke Mahavir Mohire
 

Similaire à GLAUCOMA PPT (20)

Glaucoma
GlaucomaGlaucoma
Glaucoma
 
Pharmacotherapy of glaucoma
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucoma
 
Ocular pharmacology ii, dr.kurinchi, 22.06.17
Ocular pharmacology ii, dr.kurinchi, 22.06.17Ocular pharmacology ii, dr.kurinchi, 22.06.17
Ocular pharmacology ii, dr.kurinchi, 22.06.17
 
Pharmacotherapy of glaucoma
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucoma
 
Glaucoma.pptx
Glaucoma.pptxGlaucoma.pptx
Glaucoma.pptx
 
Ocular pharmacology
Ocular pharmacologyOcular pharmacology
Ocular pharmacology
 
Mellss yr4 opthalmology glaucoma primary open angle
Mellss yr4 opthalmology glaucoma  primary open angleMellss yr4 opthalmology glaucoma  primary open angle
Mellss yr4 opthalmology glaucoma primary open angle
 
Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...
Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...
Acute Congestive Glaucoma / Optic Neuritis / Painful Loss Of Vision by Dr. Mu...
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 
Primary open angle glaucoma (poag)
Primary open angle glaucoma (poag)Primary open angle glaucoma (poag)
Primary open angle glaucoma (poag)
 
Primary open angle glaucoma(POAG)
Primary open angle glaucoma(POAG)Primary open angle glaucoma(POAG)
Primary open angle glaucoma(POAG)
 
recent advances in pharmacotherapy of Glaucoma
recent advances in pharmacotherapy of Glaucoma recent advances in pharmacotherapy of Glaucoma
recent advances in pharmacotherapy of Glaucoma
 
Pharmacotherapy & recent advances in glaucoma management
Pharmacotherapy & recent advances in glaucoma managementPharmacotherapy & recent advances in glaucoma management
Pharmacotherapy & recent advances in glaucoma management
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 
Primary open angle glaucoma
Primary open angle glaucomaPrimary open angle glaucoma
Primary open angle glaucoma
 
primaary open angle glaucoma presentation
primaary open angle glaucoma presentationprimaary open angle glaucoma presentation
primaary open angle glaucoma presentation
 
Glaucoma
GlaucomaGlaucoma
Glaucoma
 
Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke
Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke  Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke
Ischemic of optic neuropathy, Optic Neuropathy (Ischemic), Eye Stroke
 
POAG.pptx
POAG.pptxPOAG.pptx
POAG.pptx
 
Drug Therapy of Glaucoma
Drug Therapy of GlaucomaDrug Therapy of Glaucoma
Drug Therapy of Glaucoma
 

Dernier

SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxAmanpreet Kaur
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibitjbellavia9
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.MaryamAhmad92
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701bronxfugly43
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structuredhanjurrannsibayan2
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...pradhanghanshyam7136
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Association for Project Management
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 

Dernier (20)

SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 

GLAUCOMA PPT

  • 3.  •Glaucoma refers to a group of ophthalmic disorders characterized by neuropathy of the optic nerve and progressive loss of retinal ganglion cells, VISUAL FIELD LOSS OPTIC NERVE DAMAGE GLAUCO MA INCREASE IOP •Which leads to permanent deterioration of the visual field eventually lead to blindness.
  • 4. ETIOLOGY • All types of glaucoma – progressive optic neuropathy due to the death of retinal ganglion cells(RGCs) • RGCs death is initiated by block in transport of neurotrophins from brain to RGCs damaging cascade activation Apoptosis of RGCs • RGCs death – loss of retinal fibers – optic neuropathy & visual field defects
  • 5. • Mechanical theory : ↑IOP – mechanical stretch of lamina cribtosa – axonal deformation & altered capillary blood flow -- ↓neurotrophins to reach RGC`s (normal IOP pressure is 5-22mm/Hg) • Pressure independent factors : - Failure of autoregulation - Vasospasm - Systemic hypotension - Blood / fluid loss • Excitotoxicity theory: glutamate , oxygen free radicals, nitric oxide.
  • 6. Intraocular pressure is a function of production of liquid aqueous humour by the ciliary processes of the eye, and its drainage through the trabecular meshwork. Aqueous humor flows from the ciliary processes into the posterior chamber, bounded posteriorly by the lens and the zonules of Zinn, and anteriorly by the iris. It then flows through the pupil of the iris into the anterior chamber, bounded posteriorly by the iris and anteriorly by the cornea. From here, the trabecular meshwork drains aqueous humor via the scleral venous sinus (Schlemm's canal) into scleral plexuses and general blood circulation. MECHANISM OF PRODUCTION OF AQUEOUS HUMOUR AND ITS OUFLOW
  • 7.
  • 8. PATHOPHYSIOLOGY A- POAG : • Increased IOP causes retinal ganglion cell axons to undergo mechanical stress, alters axonal protein transport, and decreases blood supply to the retina and the optic nerve leading to tissue ischemia. • The level of IOP is related to the death of retinal ganglion cell and optic nerve fibers.
  • 9. B- PACG : Involves Two major mechanisms of Mechanical obstruction of trabecular meshwork by the peripheral iris include 1- Pupillary block (more common) 2- Iris plateau. • Both of these mechanisms result in the occlusion of aqueous humor outflow causing IOP elevation at extreme levels that can lead to vision loss in hrs to days.
  • 11. CLINICAL MANIFESTATION  A- POAG: General • POAG is usually bilateral with asymmetric disease progression Symptoms: 1. Loss of peripheral vision. 2. Presence of scotomata (blind spots) in vision field. Signs: Ophthalmoscopic examination may reveal 1.Optic nerve head (optic disc) cupping. 2.Large cup-to-disc ratio. 3.Notching of the optic nerve head rim. 4.Splinter hemorrhages (using a slit-lamp biomicroscope)
  • 12. B- PACG: General (Medical emergency due to high risk of vision loss) • Unilateral in presentation , the other eye is at risk. Symptoms 1. Ocular pain. 2. Red eye. 3. Blurry vision. 4. Halos around lights. • Nausea/vomiting. • Headache / Diaphoresis. Signs 1. Cloudy cornea 2. Conjunctival hyperemia. 3. Pupil semidilated and fixed to light 4. Eye will be harder on palpation.a
  • 13. DIAGNOSIS Eye pressure test (intraocular pressure). Anterior chamber angle exam. Optic angle exam. Visual field test.
  • 14. TREATMENT : 1. NON PHARMACOLOGICAL TREATMENT. 2. PHARMACOLOGICAL TREATMENT.
  • 15. Non pharmacol -ogical treatment 1. Eat healthy diet 2. Maintain good health 3. Avoid stress 4. Go for aromatothe rapy, acupunctur e. 5. Avoid caffeine, alcohol, watching tv etc.,. 6. Avoid allergic foods. NON PHARMACOLOGICAL TREATMENTS
  • 16. PHARMACOLOGICAL TREATMENT  Ophthalmic Drugs for Glaucoma Lowering IOP by 1-REDUCING PRODUCTION OF AQUEOUS HUMOR: β-Blockers. α2Adrenergic Agonists Carbonic Anhydrase Inhibitors. 2-DECREASING THE RESISTANCE TO OUTFLOW OF AQUEOUS HUMOR THROUGH TRABECULAR MESHWORK: cholinergics and cholinesterase inhibitors. 3-IMPROVING THE OUTFLOW OF AQUEOUS HUMOR: prostaglandins (uveoscleral outflow) sympathomimetics (trabecular meshwork and the uveoscleral outflow).
  • 17. A.TOPICAL Β-ADRENERGIC BLOCKING DRUGS Includes: 1. Non-selective: Timolol, Levobunolol, Metipranolol & Carteolol. 2. β1-Selective: Betaxolol. -Dosing: 1 drop BID -Side effects: 1- Bronchospasm. 2- Bradycardia. 3- Hypotension. 4- CHF exacerbation. 5- Mask hypoglycemia. 6- Tachyphylaxis (20% to 50% of pts) . -Nasolacrimal occlusion is a technique to decrease amount of drug absorbed systemically and decrease the incidence of side effects and improve medication effectiveness. Contraindications 1- Asthma 2- COPD 3- Sinus bradycardia 4- 2nd or 3rd degree heart failure 16 Betanolol can be used
  • 18. B. A2-ADRENERGIC AGONISTS -Includes: Brimonidine(more selective) & Apraclonidine. -Brimonidine: (Effective long-term monotherapy / adjunctive therapy) - Apraclonidine (Short-term use only due to high rate of tachyphylaxis) Used for prevention & ttt of postsurgical IOP elevations. -Dosing: 1 drop BID to TID. -Side effects: 1-Blepharoconjunctivitis. 2-Foreign body sensation. 3-Papillary mydrasis (Apraclonidine). 4-Eyelid retraction(Apraclonidine). 5-Mild systemic hypotension and lethargy. ( Brimonidine pass BBB ). Contraindications 1. hypersensitivity. 2. Patients receiving MOA inhibior therapy.
  • 19. C. CARBONIC ANHYDRASE INHIBITORS 1- Topical agents : -Includes: Dorzolamide and Brinzolamide. -Dosing: 1 drop BID with beta blockers or TID alone. -Combination of Timolol+Dorzolamide is commonly used -Side effects: 1-Burning. 2-Stinging. 3-Itching. 4-Dry eyes. 5-Conjunctivitis Contraindications patients with history of hypersensitivity to sulphonamides.
  • 20. 2- Orally-administered CAIs: -Includes: Acetazolamide , Dichlorphenamide, and Methazolamide. -Dosing: 250-1000mg daily , given in divided doses for amount over 250mg. -Side effects: 1-Paresthesia of hands and feet. 2-Hypokalemia and hyponatremia. 3-Nephrolethiasis and renal failure. 4-Hepatic insufficiency. 5-Blooddyscrasias from bone marrow suppression Contraindications: 1-Hypokalemia. 2-Hyponatremia
  • 21. D. CHOLINERGICS AND CHOLINESTERASE INHIBITORS 1- CHOLINERGICS: -Includes: Pilocarpine and Carbachol. -Dosing:1–2 drops TID or QID. -Used with caution for closed angle -Side effects:(due to miosis) 1-Brow ache and headache. 2-Affect night vision. 3-Bradycardia at high conc. 4-Retinal detachment. 5-Lacrimation, myopia, blurred vision. Contraindications: 1. Severe myopia to avoid detachment. 2. pregnancy
  • 22. 2- CHOLINESTERASE INHIBITORS: Includes: Echothiophate iodide &Demecarium bromide. -Irreversible AchE inhibitors e’ long durations of action. -Stop at least 1 week before general surgical procedure. Dosing: 1 drop BID. Side effects: 1- Depletion of systemic cholinesterase and pseudocholinesterase. 2- Cataracts: occur in 30–50% of elderly patients using these drugs for at least 6 months.
  • 23. E. PROSTAGLANDINS Includes: Latanoprost, Bimatoprost, Travoprost. -First-line alternatives to topical β-blockers. -Patients required to lower IOP by greater than 25%. -Lower IOP by 25% to 35% (Lower nocturnal IOP). Dosing: 1 drop once a day at bedtime Side effects: 1- Conjunctival hyperemia. 2- Stinging on instillation.3- Inc. in iris pigmentation. 4- Hypertrichosis. 5- Eyelashes darkening.
  • 24. F. SYMPATHOMIMETICS Includes: DIPIVEFRIN HCL , EPINEPHRINE. -IOP is reduced by 20–25%. -Last line agents due to their systemic S.E. Profile Dosing:1 drop BID. Intolerance to ocular adverse effects leads to discontinuation of epinephrine in 80% of patients. Side effects: 1-Burning, tearing. 2-Reactive conjunctival hyperemia. 3-Allergic blepharoconjunctivitis. 4-Mydriasis → Blurring of vision.